ScoreComparison
Company
Score
Quality
Valuation
Financial
Technical
Why is Milestone Pharmaceuticals, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate -4.87% of over the last 5 years
2
Negative results in Mar 26
- OPERATING CASH FLOW(Y) Lowest at USD -51.24 MM
- ROCE(HY) Lowest at -456.88%
- INTEREST(Q) Highest at USD 4.14 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -29.05%, its profits have fallen by -51.9%
4
Below par performance in long term as well as near term
- Along with generating -29.05% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Milestone Pharmaceuticals, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Milestone Pharmaceuticals, Inc.
-29.05%
-0.15
86.30%
S&P 500
20.78%
1.56
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
20.59%
EBIT Growth (5y)
-4.87%
EBIT to Interest (avg)
-36.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
0.03
Tax Ratio
0.54%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
35.96%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.93
EV to EBIT
-1.19
EV to EBITDA
-1.19
EV to Capital Employed
-11.69
EV to Sales
48.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-150.97%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend13What is working for the Company
NET PROFIT(HY)
Higher at USD -43.48 MM
RAW MATERIAL COST(Y)
Fallen by -7,059% (YoY
NET SALES(9M)
Higher at USD 1.78 MM
CASH AND EQV(HY)
Highest at USD 290.18 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -130.07 %
INVENTORY TURNOVER RATIO(HY)
Highest at 0.17 times
DEBTORS TURNOVER RATIO(HY)
Highest at 0.5 times
-28What is not working for the Company
OPERATING CASH FLOW(Y)
Lowest at USD -51.24 MM
ROCE(HY)
Lowest at -456.88%
INTEREST(Q)
Highest at USD 4.14 MM
OPERATING PROFIT(Q)
Lowest at USD -23.72 MM
PRE-TAX PROFIT(Q)
Lowest at USD -26.18 MM
NET PROFIT(Q)
Lowest at USD -26.07 MM
Here's what is working for Milestone Pharmaceuticals, Inc.
Net Sales
At USD 1.78 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Cash and Eqv
Highest at USD 290.18 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at -130.07 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Inventory Turnover Ratio
Highest at 0.17 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Debtors Turnover Ratio
Highest at 0.5 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Net Sales
Higher at USD 1.78 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Raw Material Cost
Fallen by -7,059% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Milestone Pharmaceuticals, Inc.
Pre-Tax Profit
At USD -26.18 MM has Fallen at -65.13%
over average net sales of the previous four periods of USD -15.85 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -26.07 MM has Fallen at -65.35%
over average net sales of the previous four periods of USD -15.76 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Interest
At USD 4.14 MM has Grown at 319.8%
period on period (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Operating Cash Flow
Lowest at USD -51.24 MM
in the last three yearsMOJO Watch
The company's cash revenues from business operations are falling
Operating Cash Flows (USD MM)
Interest
Highest at USD 4.14 MM
in the last five periods and Increased by 319.8% (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
Operating Profit
Lowest at USD -23.72 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (USD MM)
Pre-Tax Profit
Lowest at USD -26.18 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -26.07 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
